Publication: Apolipoprotein D expression in substantia nigra of Parkinson disease
Loading...
Date
2006
Authors
Ordóñez, Cristina ; Navarro, A. ; Pérez, C. ; Astudillo, Aurora ; Martinez, E. ; Tolivia, J.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Apolipoprotein D (apo D), a lipocalin
transporter of small hydrophobic molecules could play
an important role in several neurodegenerative diseases.
However, its role in those diseases remains unclear.
Increments of apo D have been reported in relation with
injury and degeneration in the nervous system. Recently
increases of apo D level have been reported in
schizophrenia, a neuropathologic disease where the
oxidative stress and lipid abnormalities may be involved.
Apo D could act as a sequestering molecule binding
excess of arachidonic acid in cells. In order to determine
the relationship between apo D expression and other
neurodegenerative pathologies related to oxidative
damage, we studied the presence of apo D in the
substantia nigra of control and Parkinson disease (PD)
subjects. We found dopaminergic neurons were not
immunoreactive for apo D, control or PD subjects.
However, surrounding glial cells showed immunostaining
for apo D and signal increases in PD cases.
These findings support the role of apolipoprotein D in
neuroprotection and the importance of glia in the amount
of this protein in the central nervous system
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.